Effect of oral zinc sulfate in reduction of jaundice in term neonates

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306031162N19

Enrollment

Registered

2013-06-17

Start date

2013-05-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

jaundice term newborns.

Interventions

zinc sulfate.

Treatment - Drugs

zinc sulfate

Eligibility

Sex/Gender

All

Age

3 Years to 28 Years

Inclusion criteria

Inclusion criteria: Inclusion: Healthy jaundiced neonates, more than 38 th weeks gestational age, birth weight more than 2500 gr and indirect bilirubin in therapeutic level Exclusion: hemolytic disease, massive hemorrhage, G6PD deficiency, sepsis, respiratory distress with ventilator support, and congenital anomaly

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decreasing serum bilirubine. Timepoint: befor intervention,24 , 48, 72 and 96 after intervention. Method of measurement: blood serum bilirobin(diazo method).	—

Secondary

Measure	Time frame
Decreasing of jaundice in neonate. Timepoint: daily. Method of measurement: date of dissconection of potothorapy.;Date of disconnection of phototrapy. Timepoint: daily. Method of measurement: decreasing of serum bilirobin below phototrapy level.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ashraf Mohammadzadeh

Neonatal Research Center

mohamadzadeha@mums.ac.ir+98 51 1852 1121

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026